FGA
LXRX icon

Fortis Group Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Fortis Group Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Hold
50,000
– – 0.02% 276
2026
Q1 		$80.5K Hold
50,000
– – 0.01% 287
2025
Q4 		$58K Sell
50,000
-7,800
-13% -$10.7K 0.01% 297
2025
Q3 		$79.8K Hold
57,800
– – 0.01% 244
2025
Q2 		$61.8K Buy
57,800
+20,000
+53% +$13K 0.01% 238
2025
Q1 		$17.4K Buy
+37,800
New +$23.8K ﹤0.01% 263

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fortis Group Advisors's LXRX Position: Q2 2026 in Review

Fortis Group Advisors held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 50,000 shares worth $120K. The position accounts for 0.02% of the portfolio, ranked #276.

Fortis Group Advisors first reported a position in LXRX in Q1 2025 and has held it in 6 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Fortis Group Advisors held 50,000 shares of Lexicon Pharmaceuticals worth $120K as of Q2 2026.
  • Fortis Group Advisors left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up 0.02% of Fortis Group Advisors's portfolio in Q2 2026, its #276 holding.
  • Fortis Group Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Fortis Group Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.